AOP Orphan to bring Thromboreductin~R to the Russian market

摘要

The pharmaceutical company AOP Orphan, a European pioneer in the field of rare diseases, is expanding its sales area for the special preparation Thromboreductin~R to include the large Russian market. This means that the drug, which represents an innovative treatment option for patients afflicted by Essential Thrombocythemia, is available in core Central European markets such as Austria, Hungary, Switzerland, Czech Republic and Poland as well as in Turkey, Israel, Kazakhstan and Russia. "We have started to offer our entire range of products, focusing on rare diseases, in Russia as well as the Middle East," says Dr. Rudolf Widmann, CEO of AOP Orphan. "These regions are exciting markets. Above all, this way we can open up new treatment possibilities for patients in these countries."